ArriVent BioPharma, Inc.
Business
ArriVent BioPharma is a clinical-stage biopharmaceutical company developing differentiated oncology medicines, with a focus on non-small cell lung cancer (NSCLC) patients. The company's lead product candidate, firmonertinib, is an EGFR mutant-selective tyrosine kinase inhibitor currently in pivotal Phase 3 trials for treatment-naive patients with uncommon EGFR mutations (exon 20 insertion and PACC mutations). ArriVent is also advancing a pipeline of next-generation antibody-drug conjugates (ADCs) including ARR-217 and ARR-002 through research collaborations and licensing agreements. The company operates globally outside greater China through in-licensing arrangements with Shanghai Allist Pharmaceuticals and partnerships with Aarvik Therapeutics, Alphamab Oncology, and Lepu Biopharma.
Summary from 10-K filed 2026-03-05
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Research and development | 153 | 79 | 65 | |
| General and administrative | 24 | 15 | 10 | |
| Total operating expenses | 178 | 94 | 75 | |
| Operating loss | −178 | −94 | −75 | |
| Interest and investment income | 11 | 14 | 5 | |
| Net loss | −166 | −80 | −69 | |
| Unrealized gain (loss) on marketable securities | 225,000 | −211,000 | — | |
| Total other comprehensive gain (loss) | 225,000 | −211,000 | — | |
| Total comprehensive loss | −166 | −81 | −69 | |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | −4.32 | −2.56 | −32.38 | |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | −4.32 | −2.56 | −32.38 | |
| Weighted-average shares of common stock outstanding, basic (in shares) | 38 | 31 | 2 | |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 38 | 31 | 2 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 46 | 74 | 150 | — | |
| Short-term investments | 267 | 145 | — | — | |
| Prepaid expenses and other current assets | 20 | 8 | 10 | — | |
| Total current assets | 333 | 227 | 160 | — | |
| Long-term investments | — | 48 | — | — | |
| Right of use assets - operating leases | 13,000 | 154,000 | 291,000 | — | |
| Deferred offering costs | 69,000 | — | 3 | — | |
| Other assets | 190,000 | 126,000 | 107,000 | — | |
| Total assets | 333 | 275 | 163 | — | |
| Accounts payable | 6 | 4 | 5 | — | |
| Accrued expenses | 20 | 13 | 7 | — | |
| Operating lease liabilities | 14,000 | 162,000 | 140,000 | — | |
| Total current liabilities | 26 | 17 | 12 | — | |
| Operating lease liabilities, net of current amount | — | 14,000 | 177,000 | — | |
| Total liabilities | 26 | 17 | 12 | — | |
| Commitments and contingencies (Note 7) | — | — | — | — | |
| Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding | — | — | — | — | |
| Common stock $0.0001 par value, 200,000,000 shares authorized; 42,452,251 and 33,706,765 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 4,000 | 3,000 | — | — | |
| Additional paid-in capital | 712 | 496 | 5 | — | |
| Accumulated deficit | −405 | −238 | −158 | — | |
| Accumulated other comprehensive income (loss) | 14,000 | −211,000 | — | — | |
| Total stockholders' equity | 307 | 258 | −153 | −85 | |
| Total liabilities and stockholders' equity | 333 | 275 | 163 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Net loss | −166 | −80 | −69 | |
| Stock-based compensation expense | 13 | 3 | 895,000 | |
| Amortization/Accretion of bond discounts/premiums | −3 | — | — | |
| Prepaid expenses and other current assets | −13 | 1 | 10 | |
| Other assets | — | −20,000 | −35,000 | |
| Accounts payable | 2 | −751,000 | 1 | |
| Accrued expenses | 7 | 6 | 2 | |
| Operating lease liabilities | −21,000 | −2,000 | 25,000 | |
| Net cash used in operating activities | −161 | −70 | −56 | |
| Purchase of short-term and long-term investments | −273 | −194 | — | |
| Sales and maturities of short-term and long-term investments | 202 | 2 | — | |
| Net cash used in investing activities | −71 | −192 | — | |
| Proceeds from issuance of common stock, net of issuance costs | 203 | 186 | — | |
| Proceeds from the exercise of stock options | 502,000 | 631,000 | 354,000 | |
| Payment of deferred financing costs | −70,000 | — | −2 | |
| Net cash provided by financing activities | 203 | 187 | 43 | |
| Net decrease in cash and cash equivalents | −29 | −76 | −13 | |
| Deferred offering costs transferred to additional paid-in-capital | 300,000 | 3 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is ArriVent BioPharma, Inc.'s CIK number?
ArriVent BioPharma, Inc.'s SEC CIK number is 0001868279 (1868279). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ArriVent BioPharma, Inc.'s SEC filings?
All of ArriVent BioPharma, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did ArriVent BioPharma, Inc. last report earnings?
ArriVent BioPharma, Inc. (AVBP) most recently filed an earnings 8-K with the SEC on May 11, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-058638). This is ArriVent BioPharma, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is ArriVent BioPharma, Inc.'s most recent earnings 8-K?
ArriVent BioPharma, Inc.'s latest earnings 8-K (Item 2.02) was filed May 11, 2026 under accession 0001104659-26-058638. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View ArriVent BioPharma, Inc.'s latest earnings 8-K →
Look up any company's CIK number →